Sibel Cinar-Asa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sibel Cinar-Asa has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Ferda Ari
Department of Biology, Faculty of Arts and Sciences, Bursa Uludag University, Bursa, Türkiye
3 shared publications - Aygun Aliyarbayova
Department of Cytology, Embryology and Histology, Azerbaijan Medical University, Baku 1001, Azerbaijan
1 shared publication - Demet Coskun
Department of Chemistry, Faculty of Science, Fırat University, 23200 Elazığ, Türkiye
1 shared publication - Elif Erturk
Vocational School of Health Services, Bursa Uludağ University, Bursa, Turkiye
1 shared publication - Gokhan Unal
Department of Pharmacology, Faculty of Pharmacy, Erciyes University, Kayseri, Türkiye
1 shared publication - Gonca Tuna
Department of Biology, Faculty of Arts and Sciences, Bursa Uludag University, Bursa, Türkiye
1 shared publication
Latest Publications
- 30 June 2026
- Published by Azerbaijan State Advanced Training Institute for Doctors named by A.Aliyev in "The Medicine and Science" scientific-practical journal named after A.Aliyev
- Vol. 2 (44) , 58-66
MACROPHAGE MIGRATION INHIBITORY FACTOR EXPRESSION IN LUNG DISEASES: AN EXPLORATORY GENE EXPRESSION PROFILING STUDY
Macrophage Migration Inhibitory Factor (MIF) is a key inflammatory cytokine implicated in immune regulation and tumour biology. Its role in lung disease, particularly in relation to tumour differentiation and clinical risk, remains incompletely understood. This study aimed to evaluate the expression pattern of MIF in lung disease using gene expression profiling, assess its variation across histological grades, and determine its association with clinical risk. A secondary data-based exploratory analysis was conducted using microarray gene expression data from 442 lung tissue samples obtained from a publicly available dataset. MIF expression was extracted using probe ID 200799_at from the Affymetrix Human Genome U133A platform. Samples stratified based on histological differentiation into well, moderate, and poorly differentiated groups. Statistical analyses included descriptive statistics, Welch’s t-test, Pearson correlation, and linear regression. MIF expression demonstrated a significant increase with decreasing tumour differentiation, with the highest levels observed in poorly differentiated tumours (11.05±0.68). Independent t-tests confirmed significant differences between all histological groups (p<0.05). However, correlation analysis revealed a weak and non-significant association with clinical risk (r=0.06, p=0.20) and regression analysis indicated minimal predictive power (R²=0.003). MIF expression is significantly associated with tumour differentiation in lung disease but lacks predictive value for clinical risk. These findings suggest that MIF serves as a marker of tumour biology rather than a standalone prognostic biomarker.
- 30 June 2026
- Published by Azerbaijan State Advanced Training Institute for Doctors named by A.Aliyev in "The Medicine and Science" scientific-practical journal named after A.Aliyev
- Vol. 2 (44) , 58-66
MACROPHAGE MIGRATION INHIBITORY FACTOR EXPRESSION IN LUNG DISEASES: AN EXPLORATORY GENE EXPRESSION PROFILING STUDY
Macrophage Migration Inhibitory Factor (MIF) is a key inflammatory cytokine implicated in immune regulation and tumour biology. Its role in lung disease, particularly in relation to tumour differentiation and clinical risk, remains incompletely understood. This study aimed to evaluate the expression pattern of MIF in lung disease using gene expression profiling, assess its variation across histological grades, and determine its association with clinical risk. A secondary data-based exploratory analysis was conducted using microarray gene expression data from 442 lung tissue samples obtained from a publicly available dataset. MIF expression was extracted using probe ID 200799_at from the Affymetrix Human Genome U133A platform. Samples stratified based on histological differentiation into well, moderate, and poorly differentiated groups. Statistical analyses included descriptive statistics, Welch’s t-test, Pearson correlation, and linear regression. MIF expression demonstrated a significant increase with decreasing tumour differentiation, with the highest levels observed in poorly differentiated tumours (11.05±0.68). Independent t-tests confirmed significant differences between all histological groups (p<0.05). However, correlation analysis revealed a weak and non-significant association with clinical risk (r=0.06, p=0.20) and regression analysis indicated minimal predictive power (R²=0.003). MIF expression is significantly associated with tumour differentiation in lung disease but lacks predictive value for clinical risk. These findings suggest that MIF serves as a marker of tumour biology rather than a standalone prognostic biomarker.
- Open Access
- 25 April 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF BIOLOGY
- Vol. 49 (2) , 198-208
Resveratrol modulates triosephosphate isomerase and mineralization in osteosarcoma cells: potential target for novel therapeutic strategies
Background/aim: Osteosarcoma, a primary malignant bone tumor, is challenging to treat due to its aggressive nature and limited therapies. Resveratrol (RES), a natural polyphenol, has potential anticancer properties. Hence, we investigated RES’s impact on osteosarcoma cells, focusing on triosephosphate isomerase (TPI) and related mechanisms. Materials and methods: RES was applied to osteosarcoma (SaOS-2) and healthy fetal osteoblast (hFOB 1.19) cells for 48 h, and cell viability was measured by SRB assay. The mode of cell death was examined using Hoechst 33342/annexin V/propidium iodide. TPI and methylglyoxal (MG) enzyme levels were determined by ELISA. The effect of RES on the mineralization mechanism was investigated using the Alizarin Red-S method. Results: Viability assays showed that RES significantly reduced SaOS-2 cell viability, while sparing hFOB 1.19 cells. RES treatment decreased TPI levels in SaOS-2 cells and induced MG accumulation, correlating with reduced TPI. RES also triggered apoptosis and reduced mineralization in osteosarcoma cells, affecting osteogenic differentiation. Conclusion: RES shows potential as a therapeutic agent targeting the glycolytic metabolism and apoptotic pathways in osteosarcoma cells and warrants further investigation for osteosarcoma treatment.
- 25 April 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF BIOLOGY
- Vol. 49 (2) , 198-208
Open AccessResveratrol modulates triosephosphate isomerase and mineralization in osteosarcoma cells: potential target for novel therapeutic strategies
Background/aim: Osteosarcoma, a primary malignant bone tumor, is challenging to treat due to its aggressive nature and limited therapies. Resveratrol (RES), a natural polyphenol, has potential anticancer properties. Hence, we investigated RES’s impact on osteosarcoma cells, focusing on triosephosphate isomerase (TPI) and related mechanisms. Materials and methods: RES was applied to osteosarcoma (SaOS-2) and healthy fetal osteoblast (hFOB 1.19) cells for 48 h, and cell viability was measured by SRB assay. The mode of cell death was examined using Hoechst 33342/annexin V/propidium iodide. TPI and methylglyoxal (MG) enzyme levels were determined by ELISA. The effect of RES on the mineralization mechanism was investigated using the Alizarin Red-S method. Results: Viability assays showed that RES significantly reduced SaOS-2 cell viability, while sparing hFOB 1.19 cells. RES treatment decreased TPI levels in SaOS-2 cells and induced MG accumulation, correlating with reduced TPI. RES also triggered apoptosis and reduced mineralization in osteosarcoma cells, affecting osteogenic differentiation. Conclusion: RES shows potential as a therapeutic agent targeting the glycolytic metabolism and apoptotic pathways in osteosarcoma cells and warrants further investigation for osteosarcoma treatment.
- 12 July 2023
- Published by Springer Nature in Iranian Journal of Science
- Vol. 47 (4) , 1057-1069
Benzofuran Substituted Chalcone Derivatives Trigger Apoptotic Cell Death Through Extrinsic Pathway in Human Lung and Breast Cancer Cells
- 12 July 2023
- Published by Springer Nature in Iranian Journal of Science
- Vol. 47 (4) , 1057-1069
Benzofuran Substituted Chalcone Derivatives Trigger Apoptotic Cell Death Through Extrinsic Pathway in Human Lung and Breast Cancer Cells